These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16093442)

  • 1. The antiproliferative agent MLN944 preferentially inhibits transcription.
    Byers SA; Schafer B; Sappal DS; Brown J; Price DH
    Mol Cancer Ther; 2005 Aug; 4(8):1260-7. PubMed ID: 16093442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological characterization of MLN944: a potent DNA binding agent.
    Sappal DS; McClendon AK; Fleming JA; Thoroddsen V; Connolly K; Reimer C; Blackman RK; Bulawa CE; Osheroff N; Charlton P; Rudolph-Owen LA
    Mol Cancer Ther; 2004 Jan; 3(1):47-58. PubMed ID: 14749475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel DNA bis-intercalation by MLN944, a potent clinical bisphenazine anticancer drug.
    Dai J; Punchihewa C; Mistry P; Ooi AT; Yang D
    J Biol Chem; 2004 Oct; 279(44):46096-103. PubMed ID: 15317822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro assessment of novel transcription inhibitors and topoisomerase poisons in rhabdomyosarcoma cell lines.
    Wolf SJ; Wakelin LP; He Z; Stewart BW; Catchpoole DR
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1059-69. PubMed ID: 19277661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structures and dynamics of DNA complexes of the desmethyl analog of the cytotoxin MLN944: Insights into activity when a methyl isn't futile.
    Serobian A; Pracey CP; Thomas DS; Denny WA; Ball GE; Wakelin LPG
    J Mol Recognit; 2020 Aug; 33(8):e2843. PubMed ID: 32253794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. XR5944: A potent inhibitor of estrogen receptors.
    Punchihewa C; De Alba A; Sidell N; Yang D
    Mol Cancer Ther; 2007 Jan; 6(1):213-9. PubMed ID: 17218634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel DNA Bis-Intercalator XR5944 as a Potent Anticancer Drug-Design and Mechanism of Action.
    Buric AJ; Dickerhoff J; Yang D
    Molecules; 2021 Jul; 26(14):. PubMed ID: 34299405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The transcription cycle of RNA polymerase II in living cells.
    Kimura H; Sugaya K; Cook PR
    J Cell Biol; 2002 Dec; 159(5):777-82. PubMed ID: 12473686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of rat liver nuclear RNA polymerase II by actinomycin D in vivo.
    Yu FL
    Carcinogenesis; 1980 Jul; 1(7):577-81. PubMed ID: 11219832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples.
    Di Nicolantonio F; Knight LA; Whitehouse PA; Mercer SJ; Sharma S; Charlton PA; Norris D; Cree IA
    Mol Cancer Ther; 2004 Dec; 3(12):1631-7. PubMed ID: 15634657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Actinomycin D inhibits human immunodeficiency virus type 1 minus-strand transfer in in vitro and endogenous reverse transcriptase assays.
    Guo J; Wu T; Bess J; Henderson LE; Levin JG
    J Virol; 1998 Aug; 72(8):6716-24. PubMed ID: 9658119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elongation by RNA polymerase II on chromatin templates requires topoisomerase activity.
    Mondal N; Zhang Y; Jonsson Z; Dhar SK; Kannapiran M; Parvin JD
    Nucleic Acids Res; 2003 Sep; 31(17):5016-24. PubMed ID: 12930951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin inhibits synthesis of ribosomal RNA in vivo.
    Jordan P; Carmo-Fonseca M
    Nucleic Acids Res; 1998 Jun; 26(12):2831-6. PubMed ID: 9611224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of anticancer drugs on transcription in vitro.
    Wilmańska D; Czyz M; Studzian K; Piestrzeniewicz MK; Gniazdowski M
    Z Naturforsch C J Biosci; 2001; 56(9-10):886-91. PubMed ID: 11724400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selectivity of F8-actinomycin D for RNA:DNA hybrids and its anti-leukemia activity.
    Takusagawa F; Takusagawa KT; Carlson RG; Weaver RF
    Bioorg Med Chem; 1997 Jun; 5(6):1197-207. PubMed ID: 9222513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation of the RNA polymerase II largest subunit during heat shock and inhibition of transcription in HeLa cells.
    Dubois MF; Bellier S; Seo SJ; Bensaude O
    J Cell Physiol; 1994 Mar; 158(3):417-26. PubMed ID: 8126066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequence-specific transactivators counteract topoisomerase II-mediated inhibition of in vitro transcription by RNA polymerases I and II.
    Brou C; Kuhn A; Staub A; Chaudhary S; Grummt I; Davidson I; Tora L
    Nucleic Acids Res; 1993 Aug; 21(17):4011-8. PubMed ID: 8396762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mithramycin selectively inhibits transcription of G-C containing DNA.
    Miller DM; Polansky DA; Thomas SD; Ray R; Campbell VW; Sanchez J; Koller CA
    Am J Med Sci; 1987 Nov; 294(5):388-94. PubMed ID: 2962490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of transcription and translation inhibitors on a human gastric carcinoma cell line. Potential role of Bcl-X(S) in apoptosis triggered by these inhibitors.
    Chang TC; Tsai LC; Hung MW; Chu LL; Chu JT; Chen YC
    Biochem Pharmacol; 1997 Apr; 53(7):969-77. PubMed ID: 9174110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol.
    Lam LT; Pickeral OK; Peng AC; Rosenwald A; Hurt EM; Giltnane JM; Averett LM; Zhao H; Davis RE; Sathyamoorthy M; Wahl LM; Harris ED; Mikovits JA; Monks AP; Hollingshead MG; Sausville EA; Staudt LM
    Genome Biol; 2001; 2(10):RESEARCH0041. PubMed ID: 11597333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.